Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-002 + lenvatinib
- Development stage
- Phase 1
- Lead developer
- ImmuneOncia Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IMC-002 + lenvatinib is an investigational combination therapy for advanced hepatocellular carcinoma (HCC), currently in Phase 1b clinical development. IMC-002 is a next-generation, fully human IgG4 monoclonal antibody targeting the CD47-SIRPα pathway to restore macrophage-mediated phagocytosis of tumor cells, while lenvatinib is an oral small molecule multi-kinase inhibitor approved as Lenvima, acting on targets such as VEGFR, FGFR, PDGFRα, KIT, and RET. IMC-002 is designed to minimize binding to normal cells and avoid hematologic toxicity. The combination is being evaluated as a second-line option for HCC patients refractory to prior treatment.
- Other names
- IMC-002 + lenvatinib
02
Targets
CD47 (Cluster of Differentiation 47)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)SIRPA (Signal-regulatory protein alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on IMC-002 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-002 + lenvatinib.